Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Medical therapy that can lower PJK rates are also being sought. Teriparatide (TP), a recombinant human parathyroid hormone (PTH 1-34), is a bone forming agent mainly used to treat osteoporotic patients with high risk of osteoporotic fracture. There has been reports suggesting protective effect of prophylactic TP to osteoporotic patients receiving ASD surgery concerning PJK.6 Although it had limitations of small sample size and surgical selection bias owing to study design being retrospective. We hypothesized prophylactic TP would act as to reduce the incidence of PJK and therefore reduce PJF and necessity of revision surgeries in patients after ASD correction surgery. Our study can consolidate the beneficial effect of prophylactic TP to patients receiving ASD surgery by reducing the incidence of PJK.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Female patients between 50 years to 80 years of age with ASD
- Multilevel instrumented fusion
- Cobb angle above 25̊ in coronal plane deformities, Lumbar lordosis below 20̊ in sagittal plane deformities
- Minimum follow-up of 1 years
Exclusion criteria
- Diagnosis being tumor or infectious condition like Tb spondylitis were excluded
- Patients with adverse reactions or contraindications to TP were excluded; side effects to TP or bone cancer or metastasis
Trial design
Primary purpose
Allocation
Interventional model
Masking
64 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal